

*SBIA DMF Workshop: GDUFA III
Enhancements and Structured Data
Submissions*

November 30, 2022

Modernization of Regulatory Submission

*Larisa Wu, PhD
Associate Director for Science and
Communication
Office of New Drug Products
OPQ, CDER, FDA*




Advancing Forward

Annually, OPQ reviews ~ 3,000 INDs, ~240 NDAs/BLAs, ~900 ANDAs, ~10,000 supplements, submitted in **unstructured** PDF format.



We recognize the need to modernize
(20th → 21st century technology)




Move from narrative information to **structured data***
in order to best capture/manage knowledge

* **Structured data** is highly specific and is stored in a predefined format, where **unstructured data** is a conglomeration of many varied types of data that are stored in their native formats

The KASA System

KASA = Knowledge-aided Assessment and Structured Application




The KASA System:

A data-based platform for structured quality assessments and applications that supports knowledge management

KASA for DS applicable to assessment of API information submitted in NDAs, ANDAs, and DMFs will be released in CDER IT platform in February 2023.

Current KASA System



The KASA System

FDA

Knowledge Management

KASA

Generics

New
Drugs

Biologics

Knowledge-Aided Assessment and
Structured Application

“KA”

integrated set of tools and framework to
aid regulatory assessment and
knowledge management

Structured Application

What information is submitted?

How is information organized?

Electronic data standards


ICH M4Q
revision

PQ-CMC

“SA”

content and organization of
submission and electronic data
standards

Future KASA System with Structured Application



How to Get There?

- Regulatory Assessment Transformation
 - KASA
- Regulatory Submission Transformation
 - Revision of ICH M4Q
 - Structured Pharmaceutical Quality Standards



U.S. FOOD & DRUG
ADMINISTRATION


Ongoing efforts related to structured applications:

- **Revision of ICH Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality – M4Q(R1)**



What is M4Q Designed to Do?

- Provides a harmonized structure and format for presenting quality information in Common Technical Document (CTD)/electronic CTD for registration of pharmaceuticals for human use
 - **Module 2 Quality Overall Summary (QOS)**
 - **Module 3 Quality**
- M4Q(R1) was developed in 2002
- Major improvement over paper/local submission formats



What Are Perceived Problems?

- M4Q(R1) is now due for revision to further improve registration and lifecycle management efficiency, leverage digital technologies, and accelerate patient and consumer access to pharmaceuticals. The specific drivers for this revision include:
 1. Several ICH regions have not fully implemented ICH M4Q(R1). The modernization will support and clarify global understanding of the CTD, enabling greater regulatory convergence and harmonization, and decrease redundancy.
 2. The M4Q(R2) guideline should align with modern quality guidelines Q8-Q14, and other relevant ICH guidelines that have been developed or given greater focus since the issuance of ICH M4Q(R1).

What Are Perceived Problems (Cont.)?

3. The M4Q(R2) guideline should provide guidance on the location of information supporting multicomponent and/or complex products, such as antibody-drug conjugates, vaccines, ATMPs/Cell & Gene Therapies & Tissue Engineered Products or combination products that meet the definition of a pharmaceutical or biological product.
4. The M4Q(R2) guideline should facilitate leveraging advances in digital tools, data management and standardization, and analytics to enhance efficiencies and effectiveness of regulatory submissions and assessments, although the structured pharmaceutical quality submission is beyond the scope of M4Q(R2) guideline.


What are the Issues to be Resolved?



Expanding the scope of M4Q(R1) guideline to include all pharmaceutical drug substances and products (both chemical and biological)



Establishing the role of M4Q(R2) as the main source of the structure and location of regulatory quality information.



Organizing product and manufacturing information in a suitable format for easy access, analysis, and knowledge management.



Incorporating concepts and data expectations presented in ICH Quality guidelines and aligning with currently recognized international standards and guidelines.



Better capturing the pharmaceutical development and the proposed overall control strategy, which should be the backbone of the revised M4Q structure.



Enhancing the Quality Module 2 to facilitate the efficiency and effectiveness of regulatory submissions and assessments.

M4Q(R2) Objectives

M4Q(R2) guideline will improve submission and assessment efficiency, resulting in accelerated access to pharmaceuticals by (6Es):

1. Encouraging global convergence of science- and risk-based regulatory approaches in the preparation of dossiers.
2. Explaining and defining the organization and positioning of information for Modules 2 and 3.
3. Enriching communication between regulators and applicants and enhancing lifecycle and knowledge management.
4. Embracing product and process innovation.
5. Enabling efficient use of digital tools for submission and assessment and preparing for the closely linked, upcoming ICH guideline on structured pharmaceutical quality submission.
6. Elucidating regulatory expectations and supporting efficient assessments, decision-making, and actions.

M4Q(R2) Work Plan

Expected Completion date	Deliverable
2021	✓ Final Concept Paper and Business Plan
2023	• ICH M4Q(R2) Step 1
2023	• ICH M4Q(R2) Step 2
2024	• Public workshops on M4Q(R2) Step 2
2025	• Step 3 and Step 4 Adoption of Final Guideline

For your expanded interest see *Business Plan M4Q(R2) Common Technical Document on Quality Guideline Endorsed by the Management Committee on 15 November 2021* [ICH Official web site : ICH](#)



U.S. FOOD & DRUG
ADMINISTRATION

Ongoing efforts related to
structured applications

- **Structured
Pharmaceutical Quality
Standards**




Pharmaceutical Quality Electronic Data Standards

- Module 3 body of data
 - Currently submitted in PDF format with unstructured pharmaceutical quality data.
 - Significantly hinders the efficiency of data exchange, quality assessment, and lifecycle knowledge management.

FDA initiated an effort to establish content standards and electronic exchange standards for submitting PQ/CMC data.

eCTD submissions with unstructured PQ/CMC data



Data Standards Development at FDA

- FDA PQ/CMC structuring and standardization is intended to be accomplished in multiple phases.
 - **Phase 1** covers the following topics: Drug Product, Drug Substance, Quality Specification, Batch Formula, Batch Analysis and Stability
 - Substantially completed by end of 2020; ~ 33% of Module 3 data
 - **Phase 2** data standards are under development, and will cover the following topics: Drug Product Manufacturing, Drug Substance Manufacturing, etc.
 - Initiated in January 2021



U.S. FOOD & DRUG
ADMINISTRATION

Structured Application for Drug Substance

Current efforts

- Form 3938 for DMFs
- SD files for chemical structures

Future efforts

- Structured DS synthetic pathway



Form 3938 for DMFs

- Provides the Agency contact and facility information in a structured format for easier use
- Improves efficiency and accuracy
- <https://www.fda.gov/drugs/drug-master-files-dmfs/drug-master-file-dmf-submission-resources>
- Contains
 - Current contact information
 - Facilities information
 - Cross-referenced DMFs
- Functional Goals
 - Pre-populate letters and communications
 - Cross-reference facility information to referencing applications
 - Flag secondary DMFs earlier in the process

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Drug Master File

Form Approved OMB No. 0910-0001
Expiration Date: March 31, 2024
See FDA Statement on next page

1. Date of Submission (Month/Year)

2. DMF Number

3. DMF Subject (Title)

4. DMF Type (Select one) ☐ a ☐ b ☐ c ☐ d ☐ e ☐ f ☐ g ☐ h ☐ i ☐ j ☐ k ☐ l ☐ m ☐ n ☐ o ☐ p ☐ q ☐ r ☐ s ☐ t ☐ u ☐ v ☐ w ☐ x ☐ y ☐ z

5. Holder Information

Holder Name

Holder DUNS Number

Holder Address

Address 1 (Street address, P.O. box, etc.)

Address 2 (Apartment, suite, and building, floor, etc.)

City

State/Province/Region

Country

ZIP or Postal Code

Holder Contact (Name of person)

Holder Contact Telephone Number (include country code, if applicable, and area code)

Holder Contact Email Address

Holder Contact FAX Number (include country code, if applicable, and area code)

6. DMF Agent (Recommended for DMF's submitted by non-FDA companies or Holder Representatives of Alternate Address)

DMF Agent Name

Agent Address

Address 1 (Street address, P.O. box, etc.)

Address 2 (Apartment, suite, and building, floor, etc.)

City

State/Province/Region

Country

ZIP or Postal Code

Agent Contact (Name of person)

Agent Contact Telephone Number (include country code, if applicable, and area code)

Agent Contact Email Address


Agent Contact FAX Number (include country code, if applicable, and area code)

FORM FDA 3938 (08/2015) Page 1 of 2

Form 3938


SD Files for Chemical Structures

- Chemical **structure-data file** format that can associate data with one or more chemical structures;
- Tables of information can be translated into structures which can then be searched.
- Other associated information is part of the structured data





Acetamide.sdf - MarvinView 14.12.15.0

File Edit View Table Structure Tools Help




#	structure	SMolName	Notes
1		Acetamide	Applicants can include text.

How SD Files help FDA?

- Errors are eliminated
- Easier to transmit structures to other regulatory bodies with the Agency
- Structures represent synthetic inputs, synthetic outputs, impurities from synthetic steps; they will receive a tag for immediate and subsequent review cycles.

Chemical name	Structure	Role	Identifiers	Additional note	Edit
ID: Chemical Name: aspirin		Drug Substance	CID: 2244 UNII: Smile: <chem>CC(=O)OC1=CC=CC=C1C(=O)O</chem>	N/A	 + x

Current Structured DS Synthetic Pathway in KASA

	Format	Function of Synthetic Step	Manufacturing Risk Control		Assessment Comment	Supporting Information Link
Assessment of Synthetic Steps	Full	Reaction	Synthetic inputs & outputs	Substance name A		Chemical Structures Library
				Substance name B		
				Substance name C		
	Full	Reaction	Control	Approach 1		Synthetic Process Design & Development, equipment, Critical Process Parameters, In-Process Controls
				Approach 2		
				Approach 3		
	Simplified	Separation/Purification	Synthetic inputs & outputs	Substance name C		Chemical Structures Library
				Substance name D		
				Substance name E		

+ control of starting materials, control of intermediates, control of reagents


Desired State: Structured DS Synthetic Pathway in Submissions



DS synthetic routes in KASA can be:

- searched
- visualized
- analyzed

Having DS synthetic pathways submitted in structured format will increase assessment efficiency, avoid transcription mistakes, and improve DS knowledge management.



Conclusion

- KASA for DS interface will be released in February 2023 for assessment of DS information submitted in DMFs, ANDAs and NDAs. It presents opportunities for knowledge management, consistency in decision making, and improved assessment efficiency.
- Efforts are ongoing at ICH (ICH M4Q(R2)) and FDA (PQ-CMC) levels to structure quality information in submissions.
- DS information can be currently submitted in a structured format, in Form 3938 for DMFs and SD files for chemical structures. It eliminates potential transcription errors and further increase assessment efficiency.



Thank You



U.S. FOOD & DRUG
ADMINISTRATION

Effective leadership Collaborative relationships

Encourage innovation Risk-based approaches

———— ***One Quality Voice*** ————

Patients first Team-based processes

Developing and utilizing staff expertise

Scientifically-sound quality standards